745 related articles for article (PubMed ID: 19033669)
1. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.
Deane R; Sagare A; Hamm K; Parisi M; Lane S; Finn MB; Holtzman DM; Zlokovic BV
J Clin Invest; 2008 Dec; 118(12):4002-13. PubMed ID: 19033669
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model.
Nishitsuji K; Hosono T; Nakamura T; Bu G; Michikawa M
J Biol Chem; 2011 May; 286(20):17536-42. PubMed ID: 21471207
[TBL] [Abstract][Full Text] [Related]
3. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
Ma Q; Zhao Z; Sagare AP; Wu Y; Wang M; Owens NC; Verghese PB; Herz J; Holtzman DM; Zlokovic BV
Mol Neurodegener; 2018 Oct; 13(1):57. PubMed ID: 30340601
[TBL] [Abstract][Full Text] [Related]
4. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
Hu J; Liu CC; Chen XF; Zhang YW; Xu H; Bu G
Mol Neurodegener; 2015 Mar; 10():6. PubMed ID: 25871773
[TBL] [Abstract][Full Text] [Related]
5. APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1.
Tachibana M; Holm ML; Liu CC; Shinohara M; Aikawa T; Oue H; Yamazaki Y; Martens YA; Murray ME; Sullivan PM; Weyer K; Glerup S; Dickson DW; Bu G; Kanekiyo T
J Clin Invest; 2019 Mar; 129(3):1272-1277. PubMed ID: 30741718
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E isoform-specific effects on lipoprotein receptor processing.
Bachmeier C; Shackleton B; Ojo J; Paris D; Mullan M; Crawford F
Neuromolecular Med; 2014 Dec; 16(4):686-96. PubMed ID: 25015123
[TBL] [Abstract][Full Text] [Related]
7. Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH.
Prasad H; Rao R
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6640-E6649. PubMed ID: 29946028
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of amyloid-β in the brain of mouse models of Alzheimer's disease is modified by altered gene expression in the presence of human apoE isoforms during aging.
Honda K; Saito Y; Saito H; Toyoda M; Abe R; Saito T; Saido TC; Michikawa M; Taru H; Sobu Y; Hata S; Nakaya T; Suzuki T
Neurobiol Aging; 2023 Mar; 123():63-74. PubMed ID: 36638682
[TBL] [Abstract][Full Text] [Related]
9. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis.
Mahan TE; Wang C; Bao X; Choudhury A; Ulrich JD; Holtzman DM
Mol Neurodegener; 2022 Feb; 17(1):13. PubMed ID: 35109920
[TBL] [Abstract][Full Text] [Related]
10. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk.
Huang YA; Zhou B; Nabet AM; Wernig M; Südhof TC
J Neurosci; 2019 Sep; 39(37):7408-7427. PubMed ID: 31331998
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.
Hashimoto T; Serrano-Pozo A; Hori Y; Adams KW; Takeda S; Banerji AO; Mitani A; Joyner D; Thyssen DH; Bacskai BJ; Frosch MP; Spires-Jones TL; Finn MB; Holtzman DM; Hyman BT
J Neurosci; 2012 Oct; 32(43):15181-92. PubMed ID: 23100439
[TBL] [Abstract][Full Text] [Related]
12. Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.
Nakamura T; Kawarabayashi T; Ueda T; Shimomura S; Hoshino M; Itoh K; Ihara K; Nakaji S; Takatama M; Ikeda Y; Shoji M
J Alzheimers Dis; 2023; 93(1):333-348. PubMed ID: 36970894
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo.
Gilat-Frenkel M; Boehm-Cagan A; Liraz O; Xian X; Herz J; Michaelson DM
Curr Alzheimer Res; 2014; 11(6):549-57. PubMed ID: 24251389
[TBL] [Abstract][Full Text] [Related]
14. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.
Youmans KL; Tai LM; Nwabuisi-Heath E; Jungbauer L; Kanekiyo T; Gan M; Kim J; Eimer WA; Estus S; Rebeck GW; Weeber EJ; Bu G; Yu C; Ladu MJ
J Biol Chem; 2012 Dec; 287(50):41774-86. PubMed ID: 23060451
[TBL] [Abstract][Full Text] [Related]
15. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
Aleshkov S; Abraham CR; Zannis VI
Biochemistry; 1997 Aug; 36(34):10571-80. PubMed ID: 9265639
[TBL] [Abstract][Full Text] [Related]
16. A flow cytometry-based
Kara E; Marks JD; Roe AD; Commins C; Fan Z; Calvo-Rodriguez M; Wegmann S; Hudry E; Hyman BT
J Biol Chem; 2018 Aug; 293(34):13247-13256. PubMed ID: 29950521
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease.
Butterfield DA; Mattson MP
Neurobiol Dis; 2020 May; 138():104795. PubMed ID: 32036033
[TBL] [Abstract][Full Text] [Related]
18. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.
Tai LM; Bilousova T; Jungbauer L; Roeske SK; Youmans KL; Yu C; Poon WW; Cornwell LB; Miller CA; Vinters HV; Van Eldik LJ; Fardo DW; Estus S; Bu G; Gylys KH; Ladu MJ
J Biol Chem; 2013 Feb; 288(8):5914-26. PubMed ID: 23293020
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
20. Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice.
Xu F; Vitek MP; Colton CA; Previti ML; Gharkholonarehe N; Davis J; Van Nostrand WE
J Neurosci; 2008 May; 28(20):5312-20. PubMed ID: 18480287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
